Our Imaging Services
Delivering scientific and operational excellence
We combine deep therapeutic understanding with extensive clinical trial experience to provide a specialized service for clinical studies in liver disease.
This includes an in-house imaging CRO and central imaging capabilities, delivered through our dedicated, secure, cloud-based portal as an end-to-end solution for study and data management.
We set high quality standards for our medical devices and biomarkers driven by a world-class team of MR physicists, biomedical engineers, imaging scientists and clinicians.
Our imaging services are delivered with equal excellence by our experienced MR applications specialists, analytics and service managers, data analysts and project managers.
What makes us different?
The only imaging CRO and vendor who can provide all MR central reads for the following – MRI-PDFF, corrected T1, Magnetic Resonance Elastography (MRE), visceral fat/adiposity, and incidental findings management.
The only provider of ‘best-in-class’ LMS IDEAL methodology for fat quantification standardized across 1.5T and 3T Siemens, Philips, and GE Scanners.
Extensive experience in NASH clinical trials. We have provided imaging CRO or vendor services for 15 NASH trials, across Phase IB to III, and have managed imaging data from >20,000 subjects in non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH) and other liver disease.
How we help clinical trials
Currently, liver biopsy is the gold standard for definitive diagnostic staging and monitoring of liver disease. Biopsy is a painful, invasive procedure. It has inherent risks and samples only a small section of the liver. The results can have huge variability when trying to quantify disease.
This presents challenges for clinical trial design, including recruitment of patients and selection of appropriate outcome measures to determine therapeutic efficacy. Differentiating patients who will progress to clinically-relevant liver disease is a further challenge. For every ten patients biopsied, only one may meet the entry criteria. These factors can make clinical trials in this area time-consuming and costly.
Our non-invasive imaging biomarkers provide quantitative metrics of liver health, including correlates of liver fat, hepatic iron, inflammation and fibrosis, which are suitable for monitoring treatment effects during interventional trials and can help you to see signals of success more quickly.
Our experience in clinical trials
Unrivalled Experience in Liver Disease
Imaging CRO services for 14 NASH trials across Phase IB to III,
Managing RADIcAL 1, a 2,000-subject randomized controlled trial for NASH
To find out more about the technology behind our metrics, take a look at our publications page.Publications